Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) CFO Molly Henderson Sells 6,583 Shares

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) CFO Molly Henderson sold 6,583 shares of the company’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $6.59, for a total transaction of $43,381.97. Following the sale, the chief financial officer now directly owns 93,546 shares in the company, valued at $616,468.14. This trade represents a 6.57 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Molly Henderson also recently made the following trade(s):

• On Thursday, December 19th, Molly Henderson sold 1,291 shares of Phathom Pharmaceuticals stock. The stock was sold at an average price of $8.00, for a total transaction of $10,328.00.

Phathom Pharmaceuticals Stock Performance

NASDAQ PHAT opened at $7.17 on Friday. The firm has a 50-day moving average of $8.08 and a 200-day moving average of $12.53. Phathom Pharmaceuticals, Inc. has a 52-week low of $6.07 and a 52-week high of $19.71.

Phathom Pharmaceuticals (NASDAQ:PHAT) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($1.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.57) by $0.25. The company had revenue of $16.35 million for the quarter, compared to analyst estimates of $12.54 million. During the same quarter last year, the business earned ($0.76) earnings per share. As a group, sell-side analysts expect that Phathom Pharmaceuticals, Inc. will post -4.74 earnings per share for the current year.

Institutional Trading of Phathom Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in PHAT. Huntington National Bank increased its position in Phathom Pharmaceuticals by 62.2% during the 3rd quarter. Huntington National Bank now owns 1,471 shares of the company’s stock worth $27,000 after buying an additional 564 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Phathom Pharmaceuticals by 41.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,470 shares of the company’s stock valued at $43,000 after acquiring an additional 722 shares in the last quarter. US Bancorp DE increased its position in Phathom Pharmaceuticals by 28.6% during the third quarter. US Bancorp DE now owns 5,248 shares of the company’s stock worth $95,000 after acquiring an additional 1,166 shares during the period. Quest Partners LLC acquired a new stake in Phathom Pharmaceuticals in the 3rd quarter worth about $197,000. Finally, Intech Investment Management LLC bought a new stake in Phathom Pharmaceuticals in the 3rd quarter valued at about $207,000. 99.01% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $28.00 target price on shares of Phathom Pharmaceuticals in a research note on Thursday, December 12th. Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 price objective on shares of Phathom Pharmaceuticals in a research report on Friday, January 10th.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.